NEW YORK (GenomeWeb) – Rosetta Genomics this week announced that it has signed a deal with an undisclosed global pharmaceutical firm to develop a microRNA-based diagnostic for the early detection of Alzheimer's disease.
Under the deal, Rosetta will provide the pharma with miRNA profiling services and expertise. Additional terms of the arrangement were not disclosed.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
